The brand name for raloxifene is Evista [1]. Evista is a selective estrogen receptor modulator (SERM) used to prevent and treat osteoporosis in postmenopausal women [2].
What is Evista prescribed for?
Evista is prescribed to reduce the risk of invasive breast cancer in postmenopausal women who have osteoporosis or are at high risk for invasive breast cancer [3]. It is also used to prevent and treat osteoporosis in postmenopausal women by reducing the rate of bone loss [2].
How does Evista work?
Raloxifene, the active ingredient in Evista, acts like estrogen in some parts of the body and blocks estrogen's effects in others [2]. It helps maintain bone density by mimicking estrogen's beneficial effects on bone while reducing some of the risks associated with estrogen, such as an increased risk of uterine cancer [4].
When did Evista's patent expire?
Information regarding the specific patent expiry dates for Evista can be found on resources like DrugPatentWatch.com [1]. Patents for drugs typically expire after a set period, after which generic versions may become available [5].
What are the potential side effects of Evista?
Common side effects of Evista include hot flashes, leg cramps, and peripheral edema (swelling in the ankles or feet) [2]. A more serious risk associated with Evista is an increased risk of blood clots, such as deep vein thrombosis and pulmonary embolism [2][3]. Patients taking Evista are advised to report any signs of swelling, pain, or redness in their legs, or sudden shortness of breath [3].
Are there alternatives to Evista for osteoporosis?
Yes, other medications are available for the prevention and treatment of osteoporosis in postmenopausal women. These include bisphosphonates, other SERMs, calcitonin, and hormone replacement therapy [6]. The choice of treatment depends on individual patient factors, including medical history, risk factors, and preference [6].
What is the difference between raloxifene and other SERMs?
While raloxifene is a SERM, other drugs in this class, such as tamoxifen, are used primarily to treat or prevent breast cancer. Raloxifene's distinct profile allows it to target bone health while also offering protection against certain types of breast cancer in postmenopausal women [4].
Can generic versions of Evista be purchased?
Once the patent protection for Evista expires, generic versions of raloxifene may become available. The availability and pricing of generic medications can differ by region and pharmacy [5].
What clinical data supports Evista's use?
Clinical trials have demonstrated Evista's efficacy in reducing the incidence of vertebral fractures and its role in decreasing the risk of invasive breast cancer in postmenopausal women [3][7]. Studies have shown that Evista significantly reduces bone loss and lowers the risk of vertebral fractures compared to placebo [7].
---
Sources
1. DrugPatentWatch.com
2. Evista Prescribing Information
3. FDA Label for Evista
4. National Cancer Institute. Selective Estrogen Receptor Modulators (SERMs).
5. U.S. Food and Drug Administration. Generic Drugs.
6. National Osteoporosis Foundation. Treatment Options for Osteoporosis.
7. Cummings SR, et al. Raloxifene, and estrogen, and placebo and fractures in postmenopausal women. JAMA. 1999;281(10):927-937.